Merck KGaA (ETR:MRK)
Germany · Delayed Price · Currency is EUR | Market Cap | 49.15B |
| Revenue (ttm) | 21.32B |
| Net Income (ttm) | 2.82B |
| Shares Out | 434.78M |
| EPS (ttm) | 6.48 |
| PE Ratio | 17.45 |
| Forward PE | 12.94 |
| Dividend | 2.20 (1.95%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 21,873 |
| Average Volume | 363,109 |
| Open | 113.25 |
| Previous Close | 113.05 |
| Day's Range | 113.25 - 114.40 |
| 52-Week Range | 103.00 - 177.00 |
| Beta | 0.64 |
| RSI | 55.90 |
| Earnings Date | Aug 7, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial StatementsNews
Merck Foundation Together with African and Asian First Ladies Mark ‘World Assisted Reproductive Technology Day’ 2025 Through Their ‘More Than a Mother’ Campaign
Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors ...
Merck KGaA: The Undervaluation Is Now Close To 13-Year Lows
MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration
Strengthens 90-year legacy of partnership between MilliporeSigma and WashU to accelerate scientific progress Strategic academic-industry alliance aims to build robust Research & Development talent pip...
Merck KGaA gets EU nod for Ezmekly
European Commission Grants Conditional Approval of EZMEKLY (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – STAMFORD,...
Europe is lagging behind in AI-specific patents: Merck KGaA
Kai Beckmann, CEO of Electronics at Merck KGaA, discusses Europe's competitiveness in AI development.
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across ...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 07.07.2...
Dr. Rasha Kelej Meets Mauritius President to Strengthen Partnership to Improve Access to Innovative and Equitable Healthcare and Empower Women in STEM
Senator, Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany met HIS EXCELLENCY MR. DHARAMBEER GOKHOOL, The President of Republic of Mauritius, during a high-level me...
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for...
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emi...
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders Neoclease gains access to MilliporeSigma’s technologies and expert support to scale its AI-designed gene-...
EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...
China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (N...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 05.06.2...
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX...
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p<0.00...
Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country
Abuja, Nigeria & Mumbai, Maharashtra, India: Merck Foundation, the philanthropic arm of Merck KGaA Germany underscored their commitment to build healthcare capacity, support girl education and break i...
EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 Enpato...
Merck KGaA 2025 Q1 - Results - Earnings Call Presentation
Merck KGaA (MKGAF) Q1 2025 Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €2.12, revenue of €5.28B; updates FY25 outlook
Merck KGaA Cuts Outlook Amid Macroeconomic Challenges
The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic conditions and foreign-exchange headwinds.